



The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β -Amyloid Efflux Across the Blood-Brain Barrier *in vitro*

OPEN ACCESS

Edited by:

Irving E. Vega,
Michigan State University,
United States

Reviewed by:

Ling Li,
University of Minnesota, United States
Baiba Kurins Gillard,
Houston Methodist Research
Institute, United States
Cheryl Wellington,
University of British Columbia,
Canada

*Correspondence:

Alysia Cox
a.cox1@campus.unimib.it

† These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience

Received: 23 January 2019

Accepted: 11 April 2019

Published: 16 May 2019

Citation:

Dal Magro R, Simonelli S, Cox A,
Formicola B, Corti R, Cassina V,
Nardo L, Mantegazza F, Salerno D,
Grasso G, Deriu MA, Danani A,
Calabresi L and Re F (2019) The
Extent of Human Apolipoprotein A-I
Lipidation Strongly Affects
the β -Amyloid Efflux Across
the Blood-Brain Barrier *in vitro*.
Front. Neurosci. 13:419.
doi: 10.3389/fnins.2019.00419

Roberta Dal Magro^{1†}, Sara Simonelli^{2†}, Alysia Cox^{1*}, Beatrice Formicola¹,
Roberta Corti¹, Valeria Cassina¹, Luca Nardo¹, Francesco Mantegazza¹,
Domenico Salerno¹, Gianvito Grasso³, Marco Agostino Deriu³, Andrea Danani³,
Laura Calabresi² and Francesca Re¹

¹ School of Medicine and Surgery, Nanomedicine Center NANOMIB, University of Milano-Bicocca, Monza, Italy,

² Dipartimento di Scienze Farmacologiche e Biomolecolari, Centro Grossi Paoletti, Università degli Studi di Milano, Milan, Italy, ³ Istituto Dalle Molle di Studi sull'Intelligenza Artificiale, Scuola Universitaria Professionale della Svizzera Italiana, Università della Svizzera Italiana, Manno, Switzerland

Much evidence suggests a protective role of high-density lipoprotein (HDL) and its major apolipoprotein apoA-I, in Alzheimer's disease (AD). The biogenesis of nascent HDL derived from a first lipidation of apoA-I, which is synthesized by the liver and intestine but not in the brain, in a process mediated by ABCA1. The maturation of nascent HDL in mature spherical HDL is due to a subsequent lipidation step, LCAT-mediated cholesterol esterification, and the change of apoA-I conformation. Therefore, different subclasses of apoA-I-HDL simultaneously exist in the blood circulation. Here, we investigated if and how the lipidation state affects the ability of apoA-I-HDL to target and modulate the cerebral β -amyloid ($A\beta$) content from the periphery, that is thus far unclear. In particular, different subclasses of HDL, each with different apoA-I lipidation state, were purified from human plasma and their ability to cross the blood-brain barrier (BBB), to interact with $A\beta$ aggregates, and to affect $A\beta$ efflux across the BBB was assessed *in vitro* using a transwell system. The results showed that discoidal HDL displayed a superior capability to promote $A\beta$ efflux *in vitro* (9×10^{-5} cm/min), when compared to apoA-I in other lipidation states. In particular, no effect on $A\beta$ efflux was detected when apoA-I was in mature spherical HDL, suggesting that apoA-I conformation, and lipidation could play a role in $A\beta$ clearance from the brain. Finally, when apoA-I folded its structure in discoidal HDL, rather than in spherical ones, it was able to cross the BBB *in vitro* and strongly destabilize the conformation of $A\beta$ fibrils by decreasing the order of the fibril structure (-24%) and the β -sheet content (-14%). These data suggest that the extent of apoA-I lipidation, and consequently its conformation, may represent crucial features that could exert their protective role in AD pathogenesis.

Keywords: HDL, apoA-I, β -amyloid, Alzheimer's disease, blood-brain barrier

INTRODUCTION

Apolipoprotein A-I (apoA-I) is involved in the generation and metabolism of high-density lipoproteins (HDL) (Zannis et al., 2006). The 28 kDa protein is synthesized in the small intestine and liver, and lipidated with cholesterol and phospholipids by the membrane-bound ATP-binding cassette transporter A1 (ABCA1) to create different subclasses of plasma HDL particles, including discoidal ones. Subsequently, a second lipidation step, mediated by LCAT, is required for maturation of nascent HDL into mature spherical lipid-rich HDL (Oram and Heinecke, 2005; Curtiss et al., 2006). During the HDL maturation process the secondary structure of apoA-I slightly changes (Sevugan Chetty et al., 2012). Therefore, in humans, HDL consist of heterogeneous subclasses, characterized according to charge, size, density, protein, and/or lipid composition. HDL are involved in removing excess cholesterol from peripheral tissues, e.g., the arterial wall, and transporting it to the liver for secretion by reverse cholesterol transport. HDL exert other protective effects, including anti-oxidative, anti-inflammatory, anti-apoptotic, and anti-infective actions (Kingwell et al., 2014).

It is well established that plasma levels of HDL cholesterol (HDL-c) and apoA-I, the major protein component of plasma HDL, inversely correlate with the development of many disorders, including cardiovascular diseases, diabetes, obesity, cancer, and infectious diseases. Dysregulated HDL metabolism has also been linked to brain disorders: a decrease in plasma levels of HDL-c and/or apoA-I are risk factors for memory decline and neurodegenerative diseases, such as Alzheimer's disease (AD) (Vitali et al., 2014).

Alzheimer's disease is the most common type of dementia and affects tens of millions of people worldwide. The amyloid hypothesis (Haass and Selkoe, 1993; Glenner and Wong, 2012; Selkoe and Hardy, 2016) proposes that β -amyloid peptide ($A\beta$), the main component of senile plaques, is the key player in AD pathogenesis. $A\beta$ monomers, derived from the proteolytic cleavage of the larger glycoprotein amyloid precursor protein, if not efficiently cleared from the brain can aggregate into different assemblies, which can then form regular fibrils and plaques.

Some evidence suggests that apoA-I might be involved in the pathogenesis of AD, but its role has not yet been elucidated. In a recent publication, Robert et al. (2017a) suggest that the risk to develop AD could be reduced when supported by high concentrations of plasma levels of HDL and apoA-I. It has also been shown that higher plasma levels of HDL and apoA-I are directly correlated with an increased MMSE and a lower risk of developing AD (Merched et al., 2000). Moreover, a reduction of hippocampal and whole brain volume and of cortical thickness has been detected in AD patients, along with lower plasma levels of apoA-I (Hye et al., 2014). In another study, reduced serum apoA-I has been detected in AD, contrarily to non-demented age-matched patients (Shih et al., 2014). This body of evidence suggests that apoA-I could play a protective role in AD pathogenesis, possibly by promoting the clearance of $A\beta$ from the brain. In favor of this hypothesis are also *in vivo* studies on AD mouse animal models, showing that cognitive deficit is prevented by apoA-I overexpression (Lewis et al., 2010), while it is worsened

by its deletion (Lefterov et al., 2010), and *i.v.*, administration of HDL reduces soluble $A\beta$ brain levels (Robert et al., 2016).

However, more research is needed to clarify its implications and no information is available concerning the possible role of distinct HDL subclasses. In this study, we investigate *in vitro* the ability of apoA-I in different lipidation states to affect $A\beta$ efflux across the BBB, using a transwell system made by immortalized human brain capillary endothelial cells.

Moreover, it is known that apoA-I is present in the brain (Elliott et al., 2010), but its mRNA has not been detected (Mahley et al., 1984; Harr et al., 1996; Huang et al., 2008). Thus, brain apoA-I is believed to be plasma derived from peripheral HDL that cross the blood-brain barrier (BBB) (Roheim et al., 1979; Pitas et al., 1987; Stukas et al., 2014; Fung et al., 2017).

Therefore, within the present study we have also investigated how the extent of apoA-I lipidation (giving rise to different HDL subclasses) affects the traversing of the BBB and the interaction with $A\beta$ aggregates; an issue that, to the best of our knowledge, has never been investigated before.

MATERIALS AND METHODS

Human Samples

Human plasma samples from healthy donors were provided by the Immunohematology and Transfusion Medicine Service (SIMT) of ASST Grande Ospedale Metropolitano Niguarda, Milan. All experimental protocols were approved by license 446-092014 CE from Ospedale Niguarda Ca' Granda and carried out in accordance with these guidelines and regulations. Informed consent was obtained from all donors. Plasma was prepared by low speed centrifugation at 4°C and lipoprotein isolation started within 6 h of blood collection.

Purification of apoA-I-HDL From Human Plasma

High-density lipoprotein ($d = 1.063\text{--}1.21\text{ g/mL}$) were purified from human plasma of healthy blood donors by sequential ultracentrifugation. Purified lipoproteins were dialyzed against saline immediately before use and were representative of the total HDL pool of human plasma. This sample was treated with chymase, which degrades small discoidal HDL particles, to obtain a fraction containing only spherical apoA-I-HDL (Favari et al., 2004). Briefly, apoA-I-HDL plasma pool was incubated with granule remnants isolated from rat mast cells ($30^\circ\mu\text{g/ml}$ of granule remnant total protein, equal to 40 BTEE Units/ml) for 2 h at 37°C. After incubation, tubes were placed on ice and centrifuged at 4°C, 12,000 rpm, for 5 min to remove the granule remnant-bound chymase, and the chymase-free supernatants were collected. The lack of discoidal, apoA-I-containing HDL was verified by non-denaturing two-dimensional (2-D) electrophoresis, in which agarose gel electrophoresis was followed by non-denaturing gradient gel electrophoresis (GGE), and immunoblotting against apoA-I. Spherical apoA-I-HDL were characterized by AFM, as described below.

Preparation of Discoidal HDL

Apolipoprotein A-I was purified from human plasma by gel-filtration chromatography (Bernini et al., 1996) and its purity (>95%) was confirmed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using Coomassie protein staining, as previously described (Schägger and von Jagow, 1987). This sample represents lipid-poor apoA-I, having few bound phospholipid molecules. Discoidal apoA-I-HDL were prepared by the cholate dialysis method using palmitoyl-oleoyl-phosphatidylcholine (POPC) and apoA-I in the weight ratio of 2.5:1 (Calabresi et al., 1997). Their size was estimated by non-denaturing GGE using precast 4–30% gels and the Pharmacia Phast System (Franceschini et al., 2013). Phospholipid content of lipid-poor apoA-I and discoidal HDL was measured by an enzymatic method and apoA-I concentration was measured by Lowry method. The final preparation of discoidal HDL contained 2 apoA-I and 205 POPC molecules. Discoidal HDL were characterized by AFM, as described below.

Atomic Force Microscopy Imaging of apoA-I-HDL

Atomic force microscopy (AFM) imaging was performed using a Nanowizard II (JPK Instruments, Berlin) scanning probe microscope operating in tapping and contact mode in air. In tapping mode imaging of A β _{1–42} fibrils, RTESP-300 (Bruker, United States) cantilevers were used with a nominal force constant of 40 N/m, a resonance frequency of 300 kHz, and a nominal tip radius 8 nm. For contact mode imaging of HDL subtypes, DNPS-10 (Bruker, United States) cantilevers were used with a nominal force constant of 0.06 N/m, and a nominal tip radius 10 nm. A detailed protocol used for the apoA-I-HDL characterization is supplied as Supplementary Information (see section “Characterization of HDL by AFM Imaging”). A wide range of areas of AFM images were analyzed using the commercial JPK image processing software and a customized image-analysis software (Matlab, MathWorks Inc, United States).

Preparation and Characterization of A β Aggregates

A β _{1–42} (Sigma–Aldrich, Milan, Italy) fibrils were prepared as described (Gregori et al., 2010; Bana et al., 2014; Mancini et al., 2016). Briefly, the peptide (1 mg/mL) was solubilized in 1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma–Aldrich, Milan, Italy), dried, resuspended in DMSO at a concentration of 5 mM, and bath sonicated for 10 min. To obtain a fibril-enriched preparation, samples were diluted to 200 μ M in 10 mM HCl and incubated at 37°C for 72 h. A β fibrils were characterized by AFM (Gregori et al., 2010). For the fibrillation process, samples were diluted to 100 μ M in 10 mM HCl and incubated at 37°C. In the reported images, A β was diluted to a final concentration of 10 μ M in 10 mM HCl and deposited on freshly cleaved mica. Images were acquired in air in tapping mode.

Preparation and Characterization of the *in vitro* Model of Blood-Brain Barrier

The *in vitro* BBB model was prepared and characterized as previously described (Mancini et al., 2016), using immortalized human brain endothelial cells (hCMEC/D3 cells) from Institut National de la Sante et de la Recherche Medicale, Paris, France. Briefly, hCMEC/D3 were seeded (60,000 cells/cm²) onto collagen-coated (8 μ g/cm² rat tail collagen type 1; Gibco, Thermo Fisher Scientific) transwell filters (polycarbonate 12-well, pore size 0.4 μ m, translucent membrane inserts 1.12 cm²; Costar) to establish a polarized monolayer. The cell monolayer separates two compartments, an apical one (0.5 ml) representing the blood and a basolateral one (1 ml) representing the brain. Cells were grown for 3 days in complete EBM-2 medium (1.4 μ M hydrocortisone, 10 mM HEPES, 1% penicillin-streptomycin, 5 μ g.mL⁻¹ ascorbic acid, and 1% chemically defined lipid concentrate) supplemented with 1 ng.mL⁻¹ basic fibroblast growth factor and 10% fetal bovine serum (FBS). After 3 days *in vitro* (DIV), medium was changed to complete EBM-2 medium supplemented with 5% FBS, and 10 mM LiCl and grown for a further 3 days. Trans-endothelial electrical resistance (TEER) was monitored with STX2 electrode Epithelial Volt-Ohm meter (World Precision Instruments, Sarasota, FL, United States). The formation of junctions was evaluated by confocal microscopy (LSM710, Carl Zeiss, Oberkochen, Germany) and by measuring the endothelial permeability (EP) to [¹⁴C-sucrose] (0.5 μ Ci) and [³H]-propranolol (0.5 μ Ci), as described (Bana et al., 2014). Cell viability was assessed by MTT assay (Bana et al., 2014).

Effect of apoA-I Lipidation on *in vitro* A β Efflux Across the BBB

Five hundred nanomolar of A β fibrils dissolved in 1 ml of complete culture medium were placed in the basolateral compartment of the transwell system, as previously described (Mancini et al., 2016). The impact of this treatment on the cell monolayer was evaluated by monitoring TEER, EP to radiolabeled probes, and cell viability, following the procedure described above. 5 nmol/ml of apoA-I in discoidal HDL, spherical HDL, or total HDL plasma pool (Merino-Zamorano et al., 2016) dissolved in 500 μ l of PBS was added to the apical compartment of the transwell. The impact on hCMEC/D3 monolayers of the treatments was determined by measuring the TEER after 3–24 h of incubation with apoA-I-HDL in the apical side of transwells. After different incubation times (up to 3 h) at 37°C, aliquots from the apical compartment were collected and the A β content was measured by ELISA assay (IBL International, Italy). The A β EP across the cell monolayer from the basolateral to the apical compartment (defined as A β efflux) was calculated as described (Bana et al., 2014; Mancini et al., 2016). As controls, 5 nmol/ml of commercially available apoA-I (Sigma-Aldrich, Milano, Italy) was dissolved in PBS and added

to the apical compartment. The $A\beta$ efflux was determined as previously described.

Effect of Lipidation of apoA-I on Its Ability to Cross the BBB *in vitro*

A total of 5 nmol/ml of apoA-I in discoidal HDL, spherical HDL, or total HDL plasma pool dissolved in 500 μ l of PBS was added to the apical compartment of the transwell and incubated at 37°C. After different times (up to 3 h) of incubation, the amount of apoA-I in the basolateral compartment was measured by ELISA assay (IBL International, Italy), and EP was calculated as described (Bana et al., 2014; Mancini et al., 2016).

Effect of apoA-I Lipidation on Preformed $A\beta$ Fibrils

Fifty micromolar $A\beta_{1-42}$ fibrils were incubated at 37°C in buffer B (PBS 15 mM and NaCl 20 mM, pH 7.4) with discoidal HDL, spherical HDL, or apoA-I-HDL plasma pool, containing 0.18 nmol/ml of apoA-I in order to mimic its low brain concentration (Roheim et al., 1979; Fagan et al., 2000). After different times of incubation an aliquot from each sample was immobilized on a freshly cleaved mica substrate, rinsed with Milli-Q water, dried under a gentle stream of nitrogen, and analyzed by AFM.

The effect of apoA-I lipidation on preformed $A\beta$ fibrils was also monitored by ThT assay (Quan et al., 2016). Briefly, 2 μ M of $A\beta$ fibrils were added with 5 μ M ThT (Sigma-Aldrich, Milan, Italy), 10 mM glycine buffer pH 8.5 in 1 cm² \times 1 cm² fluorimeter quartz cuvettes equipped with hermetic tips to prevent evaporation. 0.0036 nmol/ml of apoA-I in discoidal HDL, spherical HDL, or total HDL plasma pool were added to the sample and the ThT fluorescence (ex. 450 nm; em. 485 nm) was monitored at 37°C under stirring with a FP8500 fluorimeter (Jasco) equipped with a 4-cells peltier-thermostated sample holder. Low $A\beta$ and apoA-I concentrations (25-fold less than in the AFM experiments) were utilized for ThT experiments since fibrils produce sizeable scattering of the fluorescence excitation light, and in order to maintain the $A\beta$:apoA-I molar ratio as in the AFM experiments.

Molecular Modeling of apoA-I

The recently obtained discoidal HDL with apoA-I (Bibow et al., 2017) without helix-5 was considered the starting point for this work (PDB ID: 2N5E). It was demonstrated by chemical shift comparison and lipid paramagnetic relaxation enhancement experiments (Bibow et al., 2017) that apoA-I with and without helix 5 are structurally similar, strongly indicating that the overall structure of apoA-I is preserved in the shortened construct considered in the present study. One hundred 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) lipid molecules were inserted as previously described (Bibow et al., 2017). This model was solvated and neutralized by adding 0.15 M Na and Cl ions. CHARMM36 force field (Huang and MacKerell, 2013) was used to define protein and lipids topologies, and TIP3P model (Jorgensen et al., 1983) was used for the water molecules. The obtained system was minimized by applying 1,000 steps

of steepest descent energy minimization algorithm, followed by preliminary NVT of 200 ps. V-rescale thermostat was applied to maintain the temperature at 300 K with a time constant of 0.1 ps (Bussi et al., 2007). An NPT of 200 ps was carried out at 300 K ($\tau = 1$ ps) and 1 atm ($\tau = 5$ ps). V-rescale (Bussi et al., 2007) and Berendsen (Berendsen et al., 1984) coupling methods were used as temperature and pressure coupling. Finally, molecular dynamics (MD) equilibration of 100 ns was performed to optimize the DMPC/apoA-I complex.

Computational Docking and MD of apoA-I in Complex With $A\beta$ Fibril

To determine the initial orientation of $A\beta$ fibrils on DMPC/apoA-I complex, a pentamer of $A\beta_{17-42}$ was extracted from the PDB model 2BEG (Lührs et al., 2005), and considered for docking experiments (Yu and Zheng, 2012). In this NMR model, each peptide monomer has the disordered N-terminal residues 1–16 missing. However, the remaining residues 17–42 were suggested to contribute the stability of the mature fibril mostly and were included in the simulation models here, as described in previous computational studies (Fan et al., 2015; Grasso et al., 2018). The $A\beta_{17-42}$ model was first docked on apoA-I using Patchdock (Schneidman-Duhovny et al., 2005). The top-scored 100 conformations were subjected to Firedock (Andrusier et al., 2007; Mashiach et al., 2008) to refine and rescore docking solutions. The top ranked molecular system was solvated in a cubic box of 13 nm³ \times 11 nm³ \times 8 nm³ and neutralized by counterions. Each system consisted of approximately 120,000 interacting particles. CHARMM36 force field (Huang and MacKerell, 2013) was used to define protein and lipids topologies, while TIP3P model (Jorgensen et al., 1983) was used for water molecules. The system was first minimized by applying the steepest descent energy minimization algorithm. Three different replicas of the same system were generated with different initial velocities to increase the statistics of MD data. A preliminary MD simulation of 100 ps was performed in NPT ensemble at 300 K ($\tau = 1$ ps) and 1 atm ($\tau = 5$ ps) by applying position restraints on the heavy atoms of the solute. V-rescale (Bussi et al., 2007) and Berendsen (Berendsen et al., 1984) coupling methods were used as temperature and pressure coupling. Finally, three production simulations were performed at 300K for 100 ns. For comparison, $A\beta_{17-42}$ alone in water was also simulated. Principal component analysis (PCA) was applied to reduce the dimensionality of the system (Deriu et al., 2016a; Grasso et al., 2016), elucidating large-scale and low-frequency modes, thus yielding collective motions related to the destabilization of the $A\beta_{17-42}$ fibril (Maisuradze et al., 2009). After the alignment of $A\beta_{17-42}$ C- α Cartesian coordinates, the covariance matrix was calculated and diagonalized. To estimate the structural order of the $A\beta_{17-42}$ model and to what extent fibrils chains are aligned, an order parameter was calculated for each MD snapshot using equation (1):

$$(1)ordP = \frac{1}{N_r} \sum_{r=17}^{42} \frac{\langle v_r, z \rangle}{\|v_r\| \cdot \|z\|} = \frac{1}{N_r} \sum_{r=17}^{42} \cos \alpha$$

where N , is the number of residues along the peptide chain; v_r is the vector joining each of the $C\alpha$ -atoms pertaining to chain A with the corresponding $C\alpha$ -atom (same residue number) of chain E; and z is the fibril axis. Values of $ordP$ close to 1 indicate the amyloid-like shape alignment, whereas values of $ordP < 1$ are typical of a distorted structure.

Statistical Analysis

Data are expressed as mean \pm SEM or SD obtained from three independent experiments, each of them in triplicate. Data were analyzed with one-tailed Student's t test for MD analysis. Data from *in vitro* transwell assays were analyzed with one-way ANOVA and the Tukey's *post hoc* test was applied. p -value < 0.05 was considered significant.

RESULTS



Characterization of apoA-I-HDL

Plasma derived HDL were analyzed by 2D-GGE (Figure 1A). Left smear represents the subclass of discoidal apoA-I-HDL and right smear represents the subclass of spherical apoA-I-HDL, as previously described (Didichenko et al., 2016). About 10–14% of apoA-I-HDL plasma pool is represented by discoidal apoA-I-HDL. This sample was treated with chymase in order to selectively degrade discoidal apoA-I-HDL, obtaining a preparation containing mature spherical apoA-I-HDL. In Figure 1B, the complete degradation of discoidal particles is evident, indicated by the disappearance of their smear. Synthetic discoidal apoA-I-HDL were also characterized by 2D-GGE (Figure 1C). As expected, the discoidal particles migrate in

the pre-beta region. The estimated diameter of HDL by 2D-GGE is 11 ± 2 nm for spherical HDL and 8.8 ± 0.2 nm for synthetic discoidal HDL.

Spherical and discoidal apoA-I-HDL were also characterized by AFM imaging (Supplementary Figure 2). Both HDL subclasses displayed visual homogeneity in size distribution and morphology (Figures 2A,B). The height statistical distributions of AFM imaging allowed discrimination between the spherical and discoidal shapes (Figure 2C) and showed that the average dimensions of the two HDL subclasses were comparable (spherical apoA-I-HDL diameter $2R_S$ 12.7 nm, discoidal apoA-I-HDL size 12.9 nm). It should be noted that the HDL sizes obtained by using 2D-GGE and AFM techniques agree qualitatively, even if there are inherent technical differences between the two methods, which do not allow direct comparison of the results.

The extent of apoA-I lipidation, determined by measuring the phospholipid content, was 92:1 mmol lipids/mmol apoA-I for synthetic discoidal apoA-I and 15:1 mmol lipids/mmol apoA-I for lipid-poor apoA-I, as calculated from our own and previously published data (Jayaraman et al., 2012).



Characterization of A β Fibrillation

The aggregation process of A β from monomers to fibrils was followed and characterized by AFM imaging. Several images were acquired at the beginning of the fibrillation ($t = 0$ h) and at successive fixed times ($t = 4, 8, 24,$ and 48 h). Representative images are illustrated in **Figure 3A**. The results showed that long fibrils were formed over time, as previously observed (Gregori et al., 2010). The aggregation is characterized by progressive formation of unbranched fibrils of constant diameter and increasing length.

The process of fibril growth can be quantitatively evaluated by considering the time evolution of the number of pixels above a fixed height threshold in the AFM images of fibril morphology (**Supplementary Figures 1, 2**). **Figure 3B** shows AFM images of A β fibrils at different incubation times with a height threshold of 1.5 nm. The percentage of pixels above a

certain threshold increases with fibril extension and density, and it can be considered as a quantitative index of the aggregation process. Threshold pixel percentages over time (**Figure 3C**) show that there is continuous A β fibril growth in length up to 48 h.

Characterization of *in vitro* BBB Model

The *in vitro* BBB model was prepared and characterized (**Figure 4**). The TEER was monitored over time and the results showed that the maximum value ($116.37 \pm 4.37 \Omega/\text{cm}^2$) was registered 6 days after seeding (**Figure 4B**). At this time point, the formation of junctions was checked by confocal microscopy and by measuring the paracellular and transcellular EP of radiolabeled sucrose and propranolol, respectively. The results showed that Claudin-5 (**Figure 4C**, stained in green) and VE-Cadherin (**Figure 4C**, stained in red), two key components of tight and adherens endothelial junctions, are formed in




FIGURE 3 | Aggregation process of A β from monomers to fibrils studied by AFM. Representative images of A β at different fibrillation stages ($t = 0, 4, 8, 24,$ and 48 h) of incubation at 37°C . **(A)** AFM images: $4 \mu\text{m}^2 \times 4 \mu\text{m}^2$, 1024×1024 -pixel, Z-scale 10 nm. **(B)** A fixed height threshold (here 1.5 nm) is applied to the AFM images in order to quantify the number of pixels above this threshold, expressed in terms of percentage with respect to the total number of pixels. The number of such pixels is proportional to the total length of the fibril i.e., to the sum of the lengths of all the deposited fibrils. In this way, it is possible to quantify the fibril growth. **(C)** Quantification of the fibrillation. Percentage of pixel above a height threshold (1.5 nm) as obtained from AFM images, plotted as a function of the incubation time at 37°C .

the hCMEC/D3 monolayer 6 days after seeding. The EP of [^3H]-propranolol and [^{14}C]-sucrose was $1.56 \pm 0.13 \times 10^{-5}$ and $3.83 \pm 0.84 \times 10^{-5}$ cm/min, respectively, suggesting that tight junctions had formed (Figure 4D). At 6 days after seeding, 500 nM of A β fibrils (characterized by AFM images, see Figure 3) were added to the basolateral compartment of the transwell system and the impact of fibrils on cell monolayer properties was checked. After 3h of hCMEC/D3 monolayer exposure to fibrils, TEER did not significantly change ($114.10 \pm 4.82 \Omega \text{ cm}^2$) nor did EP of *trans*- and *para*-cellular probes (Figure 4D). Moreover, the treatment did not affect cell viability (>95% cells viability with respect to untreated cells), as assessed by MTT assay.


The impact on hCMEC/D3 monolayers of the different subclasses of apoA-I-HDL was determined by

measuring the TEER after 3 and 24 h of incubation with particles in the apical side of transwells. The results showed that the treatments of cell monolayers with HDL did not affect their bioelectrical properties, with TEER values of $114 \pm 11 \Omega \cdot \text{cm}^2$ after treatment (Supplementary Table 1).

Effect of apoA-I Lipidation on *in vitro* A β Efflux Across the BBB


The A β efflux from the basolateral compartment of the transwell when apoA-I in different lipidation states were present in the apical compartment was measured by ELISA assay (Supplementary Figure 5).

The presence of apoA-I in the apical compartment significantly increased A β efflux from the basolateral side



of the BBB model (Figure 5A). In particular, the ability of apoA-I to enhance the $A\beta$ efflux increased with the increase of its lipidation state, reaching maximum $A\beta$ efflux when discoidal apoA-I-HDL were present in the apical compartment.

The discoidal apoA-I-HDL significantly increased $A\beta$ efflux from the basolateral side of the BBB model, compared to the apoA-I-HDL plasma pool ($p = 0.0016$) and spherical apoA-I-HDL ($p = 0.011$) (Figure 5B).



In vitro BBB Crossing of apoA-I-HDL

Different subclasses of apoA-I-HDL were added to the apical compartment of the transwell system and their EP across the cell monolayer was estimated by measuring the apoA-I content in the basolateral compartment by ELISA assay for up to 3 h. The results (Figure 6) showed that discoidal HDL displayed higher EP values (with a passage of $1.8 \pm 0.6\%$ of apical apoA-I), compared to spherical ones ($p = 0.004$), and lipid-free apoA-I ($p = 0.048$).

Effect of apoA-I Lipidation on Preformed $A\beta$ Fibrils

The effect of apoA-I lipidation on the disaggregation of preformed $A\beta$ fibrils was assessed by AFM and thioflavine T (ThT) assay (Quan et al., 2016). $A\beta$ fibrils were incubated with apoA-I in different lipidation states for up to 24 h and changes in the morphology of fibrils were followed by AFM imaging (Figure 7). The results showed that, starting from mature $A\beta$ fibrils of comparable length (Figure 7A, row 1), the incubation with spherical apoA-I HDL did not induce significant changes in fibril morphology, and concentration (Figure 7A, column 2) compared to $A\beta$ fibrils alone (Figure 7A, column 1). On the contrary, incubation with both the apoA-I-HDL plasma pool (Figure 7, column 3) and discoidal apoA-I-HDL (Figure 7A, column 4) induced a strong time-dependent reduction of fibril concentration and extension.


The percentage of pixels above the 1.5 nm threshold (determined as reported in Supplementary Figure 1) normalized with respect to the starting point (value at $t = 0$ h) is reported for each sample at different times to obtain a quantitative analysis of AFM images. The results (Figure 7B) demonstrate the superior capability (1.6-fold increase) of discoidal apoA-I-HDL in disassembling preformed $A\beta$ fibrils compared to spherical apoA-I-HDL.

The β -sheet content of $A\beta$ fibril samples were analyzed using a ThT fluorescence assay and the results (Figure 7C) showed that when fibrils are in incubation alone or with spherical apoA-I-HDL, their β -sheet content did not significantly change. On the contrary, the presence of apoA-I-HDL plasma pool induced a 40% reduction in β -sheet content after 18 h, and there is an almost complete disruption of β -sheet structures within 4 h in the presence of discoidal apoA-I-HDL.

Discoidal apoA-I-HDL Induce a Structural Destabilization of $A\beta$

The interaction between discoidal apoA-I-HDL and $A\beta_{17-42}$ was evaluated using MD simulations. Protein structural stability was analyzed by monitoring the time evolution of the root mean square deviation (RMSD) of $A\beta_{17-42}$ in water and $A\beta_{17-42}$ in complex with apoA-I. Three different replicas of the $A\beta_{17-42}$ alone in water and in complex with apoA-I were examined to increase the statistics of the MD data. It was observed that protein conformational stability was reasonably reached in the last 20 ns of the simulations (Supplementary Figure 3). The apoA-I- $A\beta_{17-42}$ contact surface, characterized by protein-lipid ($A\beta$ -1,2-dimyristoyl-sn-glycero-3-phosphocholine) and protein-protein ($A\beta$ -apoA-I) interactions, covers 6.3 ± 2 nm² of solvent accessible surface. The hydrophobic interaction plays a pivotal role in the contact area (Supplementary Figure 4). The visual inspection of the apoA-I- $A\beta_{17-42}$ complex through the MD simulation is reported in Figure 8A and highlights the conformational destabilization of the $A\beta_{17-42}$ due to the interaction with apoA-I.

The previously highlighted conformational instability can be quantified by analyzing the fibril order parameter (*ordP*), as reported in Figure 8B. A significantly decreased *ordP* value (*ordP* < 1 are typical of a distorted structure) was found in the case of apoA-I- $A\beta_{17-42}$ (*ordP* = 0.60 ± 0.02) compared







FIGURE 7 | Disaggregation of preformed A β fibrils in the presence of HDL. **(A)** Representative AFM images of A β fibrils over time, incubated at 37°C either alone (column 1) or with different HDL subclasses: spherical HDL (column 2), total HDL plasma pool (column 3), discoidal HDL (column 4). Images are 4 $\mu\text{m}^2 \times 4 \mu\text{m}^2$, 1024 \times 1024-pixel, Z-scale 10 nm. **(B)** The normalized percentage of pixels with a height above a threshold of 1.5 nm (white pixel percentage) is reported for A β in the presence of the different HDL subclasses at different incubation times. Values are the average of pixels higher than the threshold over several images acquired on the same sample. Error bars represent SD. Each sample is normalized to its respective starting point (value at $t = 0$ h). **(C)** Thioflavine T fluorescence as a function of time in samples containing 2 μM A β fibrils alone (blue dotted) or incubated with spherical HDL (green dotted), total HDL pool (orange dotted), or discoidal HDL (purple dotted). The intensities were normalized to the respective zero-time intensity.

to A β_{17-42} alone in water ($ordP = 0.79 \pm 0.02$). The PCA provides another image, which highlights the large-scale and low frequency modes mainly related to the distortion of the A β fibril. After the alignment of the A β C- α atoms, the covariance matrix was calculated, and diagonalized for each simulated system (A β_{17-42} in water and A β_{17-42} in complex with apoA-I). The amplitude of the first Principal Component Vector, which takes into account more than 50% of the total variance of the protein motion, is reported in **Figure 8C**, highlighting a marked increase of conformational fluctuations when A β_{17-42} is in complex with apoA-I ($eigval_{PCA1} = 17$) compared to A β_{17-42} alone in water ($eigval_{PCA1} = 5$). Finally, a decreased β -sheet content was observed by computing the secondary structures probabilities (**Figure 8D**) along the A β

fibril chains at the equilibrium, as previously described (Deriu et al., 2014, 2016b; Grasso et al., 2015, 2016, 2017; Janaszewska et al., 2017). Despite the beta-sheet percentage decreases only by 14%, this is a statistically significant molecular event observed only in the apoAI-A β molecular system in the simulated time-scale of 100 ns. Moreover, the marked loss of structural order, quantified by fibril order parameter, will further affect the beta-sheet percentage in longer time-scale. Within this framework, our results clearly show a molecular event not observed in the A β system in water environment, i.e., the ability of apoA-I protein to affect the conformational stability of A β in the investigated time-scale of 100 ns.

We note that, notwithstanding the different experimental and simulative approaches, the ThT and simulation techniques



both suggest a relevant role in A β destabilization induced by discoidal HDL.

DISCUSSION

Considerable evidence suggests that plasma HDL, as well as having vasoprotective functions, could exert a protective role in AD (Kingwell et al., 2014; Vitali et al., 2014), and but the mechanisms involved have not been thoroughly investigated. Since A β clearance from the brain, a way to counteract the onset or progression of AD, partially occurs across the brain vasculature (Bates et al., 2009), and it is essential to

understand if and how circulating HDL might affect A β passage across the BBB.

Considering previously published data about the ability of HDL and apoA-I to bind A β *in vitro* (Koldamova et al., 2001; Paula-Lima et al., 2009; Shih et al., 2014) and reduce A β levels in the brain of AD animal models (Robert et al., 2016), we hypothesized that plasma-derived HDL acts by accelerating the A β egress from the brain to the blood via “sink effect,” as already speculated for different A β binding molecules or particles (Golabek et al., 1995; Mancini et al., 2016).

To investigate this issue, we used a simple BBB model consisting of an hCMEC/D3 monolayer that separates a basolateral compartment containing A β fibrils to mimic the

AD brain from an apical one containing different human HDL subclasses, and mimicking the blood. We chose to carry out the experiments on fibrils, since we have already shown, using the same BBB model system utilized in the present investigation, that oligomers are able to exit from the brain side either spontaneously or by “sink effect” induced by A β -binding liposomes (Mancini et al., 2016).

The results showed that the presence of apoA-I in the apical compartment of the transwell system strongly enhanced the A β egress from the basolateral one. This effect is dependent on the lipidation of apoA-I, reaching the maximum A β efflux when apoA-I is folded in discoidal HDL. Actually, no effect on A β efflux was detected when apoA-I was contained in mature spherical HDL. It should be noted that other lipid-based nanoparticles functionalized with A β ligands (Mancini et al., 2016) showed the ability to promote A β clearance, however with a lower efficiency compared to discoidal HDL.

Our results suggest the possibility that the apoA-I conformation, which depends on its lipidation state, may be also involved. In fact, the flexible apoA-I molecule adapts its structural motif to stabilize the different HDL subclasses (Silva et al., 2008; Phillips, 2013).

Therefore, we theorize that the plasma profile of HDL subclasses could differ between healthy and AD patients, thus affecting A β clearance from the brain. A recent study showed that HDL from AD patients were less functional compared to HDL from healthy subjects (Camponova et al., 2017), supporting this idea. Since only small soluble A β assemblies, and not fibrils, are able to cross the endothelial monolayer (Mancini et al., 2016), and since apoA-I is not synthesized in the brain (Demeester et al., 2000; Koch et al., 2001), the herein shown ability of apoA-I-HDL to promote the A β clearance across the BBB should assume their ability to cross the barrier and to disaggregate fibrils.

To verify this speculation, we tested the ability of HDL subclasses to cross the BBB *in vitro*.

Our results show that when apoA-I folded its structure in discoidal HDL, rather than in spherical particles, it was able to cross the BBB *in vitro*, suggesting that the lipidation state of apoA-I could be a key determinant affecting these features. Moreover, we found that the apical/basolateral ratio of apoA-I in our model system is comparable with the plasma/CSF ratio. Concerning the mechanism of apoA-I crossing, it should be noted that previous work suggests that the SR-BI receptor is highly selective for lipid uptake, and excludes apoAI and apoAII (Acton et al., 1996; Gillard et al., 2017). Therefore, our speculation is that apoA-I crosses the BBB through a mechanism involving the LDL receptor-related protein family, as previously suggested (Merino-Zamorano et al., 2016), and that the shape and size of HDL could be additional determining factors (Fernández-de-Retana et al., 2017).

To the best of our knowledge, the data about the ability of different HDL subclasses to cross the BBB reported in this investigation have never been published before.

Finally, we investigated the effect of different apoA-I-HDL subclasses on pre-formed A β fibrils by AFM imaging, ThT assay, and MD simulation. AFM imaging showed that the presence of discoidal apoA-I-HDL strongly reduced the amount and

concentration of long fibrils. This was confirmed by ThT assay, where a strong, and rapid reduction of the β -sheet content of fibrils was detected. The molecular modeling results highlighted the conformational destabilization of A β upon its interaction with apoA-I when associated to discoidal HDL. A significant distortion of the fibril order and a decrease in the β -sheet content was identified, clearly suggesting a key role played by discoidal apoA-I-HDL in destabilizing the A β fibrils.

Taken all together the data reported in present investigation, suggest that apoA-I-HDL action is not only peripheral via “sink effect,” but also central after BBB crossing.

In summary, we can speculate that at earliest stages of AD, discoidal apoA-I-HDL species in plasma, more than alternatively lipidated HDL species, may be involved in synergic activity with brain discoidal apoA-I-HDL pool: the central HDL pool maintains A β in a soluble form, while the peripheral HDL pool enhances its efflux from the brain. These results add new information to previously published knowledge (Robert et al., 2016, 2017b; Slot et al., 2017), suggesting that the lipidation state of apoA-I, and its conformation may be an important determinant for its role in preventing β -amyloidosis, and therefore may influence the pathogenesis of AD.

Our results are also in agreement with a previously published study about the ability of apoA-I-HDL to promote clearance of A β through the cerebral vessel (Robert et al., 2017b) in a more advanced 3D cerebrovascular model. Our data adds new insights about the potential ability of discoidal HDL to cross the BBB and to destroy A β aggregates enhancing its clearance from the brain.

Considering that the main brain apoprotein, apoE, promotes A β aggregation (Dafnis et al., 2016), we can speculate that the ratio with brain apoA-I, promoting disaggregation, may be an important key point in modulating the peptide aggregation/disaggregation paradigm. Moreover, considering that apoE in the blood is able to promote A β clearance from the brain (Robert et al., 2017b) its coupling with the disaggregating activity of brain apoA-I could play an important role in brain A β clearance. Finally, considering that A β cleared into the blood interacts with circulating apoA-I, preventing its aggregation and reducing its accumulation in the vasculature (Handattu et al., 2009; Lefterov et al., 2010; Lewis et al., 2010; Robert et al., 2016, 2017a; Fernández-de-Retana et al., 2017) depicts a complex interplay among these apolipoproteins in the brain and in the blood.

However, the synergic action between different lipoproteins in modulating A β aggregation/disaggregation and transport across the BBB will be an important issue to be investigated.

As a final consideration, it should be pointed out that the results herein reported have been obtained using an *in vitro* model. Evidently, the neurovascular unit (NVU), the area where these processes naturally occur, is considerably more complex than endothelial cells alone (Sagare et al., 2012). Indeed, the brain capillary endothelial cells of the BBB do not function alone, but they work in synergy within a context of a multicellular NVU, which includes neurons, astrocytes, pericytes, and microglia and the blood vessels themselves (McConnell et al., 2017). The NVU components cooperate to regulate cerebrovascular function and permeability

through the vasculature, which has unique structure along the vascular tree in the brain (Andreone et al., 2017). Thus, different structures can contribute to $A\beta$ exchange across the BBB. Accordingly, our results should be taken as an indication that will deserve confirmation on a model closer to the physiological state (Robert et al., 2017a) or *in vivo* in animal models.

ETHICS STATEMENT

Human plasma samples from healthy donors were provided by the Immunohematology and Transfusion Medicine Service (SIMT) of ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. All experimental protocols were approved by license 446-092014 CE from Ospedale Niguarda Ca' Granda and carried out in accordance with these guidelines and regulations. Written informed consent was obtained from each donor and all donors were over the age of 18.

AUTHOR CONTRIBUTIONS

RD performed *in vitro* experiments on the blood-brain barrier model. SS purified, prepared, and characterized the different subtypes of HDL from human plasma. AC performed *in vitro*

experiments with beta-amyloid peptide. BF prepared and characterized beta-amyloid aggregates. RC and VC performed AFM imaging experiments. LN performed ThT fluorescence assays. DS performed statistical analysis of data. GG, MD, and AD performed the molecular modeling analysis. LC, FM, and FR contributed to the data interpretation and participated in the drafting of the manuscript. FR coordinated the study, designed the experiments, and analyzed the data. All authors contributed to the manuscript revision, read and approved the submitted version, and agreed to be accountable for all the aspects of the work.

FUNDING

This work was supported by the Grant JPND-COFUND_FP-829-031 (2016–2019) to FR.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fnins.2019.00419/full#supplementary-material>

REFERENCES

- Acton, S., Rigotti, A., Landschulz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996). Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 271, 518–520. doi: 10.1126/science.271.5248.518
- Andreone, B. J., Chow, B. W., Tata, A., Lacoste, B., Ben-Zvi, A., Bullock, K., et al. (2017). Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. *Neuron* 94, 581–594.e5. doi: 10.1016/j.neuron.2017.03.043
- Andrusier, N., Nussinov, R., and Wolfson, H. J. (2007). FireDock: fast interaction refinement in molecular docking. *Proteins* 69, 139–159. doi: 10.1002/prot.21495
- Bana, L., Minniti, S., Salvati, E., Sesana, S., Zambelli, V., Cagnotto, A., et al. (2014). Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect $A\beta$ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. *Nanomedicine* 10, 1583–1590. doi: 10.1016/j.nano.2013.12.001
- Bates, K. A., Verdile, G., Li, Q. X., Ames, D., Hudson, P., Masters, C. L., et al. (2009). Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. *Mol. Psychiatry* 14, 469–486. doi: 10.1038/mp.2008.96
- Berendsen, H. J. C., Postma, J. P. M., Gunsteren, W. F. V., DiNola, A., and Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. *J. Chem. Phys.* 81, 3684–3690. doi: 10.1063/1.448118
- Bernini, F., Calabresi, L., Bonfadini, G., and Franceschini, G. (1996). The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux. *Biochim. Biophys. Acta* 1299, 103–109. doi: 10.1016/0005-2760(95)00200-6
- Bibow, S., Polyhach, Y., Eichmann, C., Chi, C. N., Kowal, J., Albiez, S., et al. (2017). Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein A-I. *Nat. Struct. Mol. Biol.* 24, 187–193. doi: 10.1038/nsmb.3345
- Bussi, G., Donadio, D., and Parrinello, M. (2007). Canonical sampling through velocity rescaling. *J. Chem. Phys.* 126:014101. doi: 10.1063/1.2408420
- Calabresi, L., Vecchio, G., Frigerio, F., Vavassori, L., Sirtori, C. R., and Franceschini, G. (1997). Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. *Biochemistry* 36, 12428–12433. doi: 10.1021/bi970505a
- Camponova, P., Le Page, A., Berrougui, H., Lamoureux, J., Pawelec, G., Witkowski, M. J., et al. (2017). Alteration of high-density lipoprotein functionality in Alzheimer's disease patients. *Can. J. Physiol. Pharmacol.* 95, 894–903. doi: 10.1139/cjpp-2016-0710
- Curtiss, L. K., Valenta, D. T., Hime, N. J., and Rye, K. A. (2006). What is so special about apolipoprotein AI in reverse cholesterol transport? *Arterioscler. Thromb. Vasc. Biol.* 26, 12–19. doi: 10.1161/01.atv.0000194291.94269.5a
- Dafnis, I., Argyri, L., Sagnou, M., Tzinia, A., Tsilibary, E. C., Stratikos, E., et al. (2016). The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific. *Sci. Rep.* 6:30654. doi: 10.1038/srep30654
- Demeester, N., Castro, G., Desrumaux, C., De Geitere, C., Fruchart, J. C., Santens, P., et al. (2000). Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. *J. Lipid Res.* 41, 963–974.
- Deriu, M. A., Grasso, G., Licandro, G., Danani, A., Gallo, D., Tuszynski, J. A., et al. (2014). Investigation of the Josephin domain protein-protein interaction by molecular dynamics. *PLoS One* 9:e108677. doi: 10.1371/journal.pone.0108677
- Deriu, M. A., Grasso, G., Tuszynski, J. A., Gallo, D., Morbiducci, U., and Danani, A. (2016a). Josephin domain structural conformations explored by metadynamics in essential coordinates. *PLoS Comput. Biol.* 12:e1004699. doi: 10.1371/journal.pcbi.1004699
- Deriu, M. A., Grasso, G., Tuszynski, J. A., Massai, D., Gallo, D., Morbiducci, U., et al. (2016b). Characterization of the AXH domain of Ataxin-1 using enhanced sampling and functional mode analysis. *Proteins* 84, 666–673. doi: 10.1002/prot.25017
- Didichenko, S. A., Navdaev, A. V., Cukier, A. M., Gille, A., Schuetz, P., Spycher, M. O., et al. (2016). Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. *Circ. Res.* 2, 751–763. doi: 10.1161/CIRCRESAHA.116.308685
- Elliott, D. A., Weickert, C. S., and Garner, B. (2010). Apolipoproteins in the brain: implications for neurological and psychiatric disorders. *Clin. Lipidol.* 51, 555–573. doi: 10.2217/CLP.10.37

- Fagan, A. M., Younkin, L. H., Morris, J. C., Fryer, J. D., Cole, T. G., Younkin, S. G., et al. (2000). Differences in the A β 40/A β 42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. *Ann. Neurol.* 48, 201–210. doi: 10.1002/1531-8249(200008)48:2<201::aid-ana10>3.0.co;2-x
- Fan, H. M., Gu, R. X., Wang, Y. J., Pi, Y. L., Zhang, Y. H., Xu, Q., et al. (2015). Destabilization of Alzheimer's A β 42 protofibrils with a novel drug candidate wxg-50 by molecular dynamics simulations. *J. Phys. Chem. B* 27, 11196–11202. doi: 10.1021/acs.jpcc.5b03116
- Favari, E., Lee, M., Calabresi, L., Franceschini, G., Zimetti, F., Bernini, F., et al. (2004). Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. *J. Biol. Chem.* 279, 9930–9936. doi: 10.1074/jbc.m312476200
- Fernández-de-Retana, S., Cano-Sarabia, M., Marazuela, P., Sánchez-Quesada, J. L., Garcia-Leon, A., Montañaola, A., et al. (2017). Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β -amyloidosis. *Sci. Rep.* 7:14637. doi: 10.1038/s41598-017-15215-w
- Franceschini, G., Favari, E., Calabresi, L., Simonelli, S., Bondioli, A., Adorni, M. P., et al. (2013). Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. *J. Clin. Lipidol.* 7, 414–422. doi: 10.1016/j.jacl.2013.06.007
- Fung, K. Y., Wang, C., Nyegaard, S., Heit, B., Fairn, G. D., and Lee, W. L. (2017). SR-BI mediated transcytosis of HDL in brain microvascular endothelial cells is independent of caveolin, clathrin, and PDZK1. *Front. Physiol.* 8:841. doi: 10.3389/fphys.2017.00841
- Gillard, B. K., Bassett, G. R., Gotto, A. M., Rosales, C., and Pownall, H. J. (2017). Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. *J. Biol. Chem.* 292, 8864–8873. doi: 10.1074/jbc.M117.781963
- Glener, G. G., and Wong, C. W. (2012). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. *Biochem. Biophys. Res. Commun.* 425, 534–539. doi: 10.1016/j.bbrc.2012.08.020
- Golabek, A., Marques, M. A., Lalowski, M., and Wisniewski, T. (1995). Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. *Neurosci. Lett.* 191, 79–82. doi: 10.1016/0304-3940(95)11565-7
- Grasso, G., Deriu, M. A., Prat, M., Rimondini, L., Vernè, E., Follenzi, A., et al. (2015). Cell penetrating peptide adsorption on magnetite and silica surfaces: a computational investigation. *J. Phys. Chem. B* 119, 8239–8246. doi: 10.1021/jp512782e
- Grasso, G., Deriu, M. A., Tuszyński, J. A., Gallo, D., Morbiducci, U., and Danani, A. (2016). Conformational fluctuations of the AXH monomer of Ataxin-1. *Proteins* 84, 52–59. doi: 10.1002/prot.24954
- Grasso, G., Rebella, M., Muscat, S., Morbiducci, U., Tuszyński, J., Danani, A., et al. (2018). Conformational dynamics and stability of U-shaped and S-shaped amyloid beta assemblies. *Int. J. Mol. Sci.* 14:19. doi: 10.3390/ijms19020571
- Grasso, G., Tuszyński, J. A., Morbiducci, U., Licandro, G., Danani, A., and Deriu, M. A. (2017). Thermodynamic and kinetic stability of the Josephin Domain closed arrangement: evidences from replica exchange molecular dynamics. *Biol. Direct* 12:2. doi: 10.1186/s13062-016-0173-y
- Gregori, M., Cassina, V., Brogioli, D., Salerno, D., De Kimpe, L., Schepers, W., et al. (2010). Stability of A β (1-42) peptide fibrils as consequence of environmental modifications. *Eur. Biophys. J.* 39, 1613–1623. doi: 10.1007/s00249-010-0619-6
- Haass, C., and Selkoe, D. J. (1993). Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. *Cell.* 75, 1039–1042. doi: 10.1016/0092-8674(93)90312-e
- Handattu, S. P., Garber, D. W., Monroe, C. E., van Groen, T., Kadish, I., Nayyar, G., et al. (2009). Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. *Neurobiol. Dis.* 34, 525–534. doi: 10.1016/j.nbd.2009.03.007
- Harr, S. D., Uint, L., Hollister, R., Hyman, B. T., and Mendez, A. J. (1996). Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. *J. Neurochem.* 66, 2429–2435.
- Huang, J., and MacKerell, A. D. (2013). CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. *J. Comput. Chem.* 34, 2135–2145. doi: 10.1002/jcc.23354
- Huang, J. T., Wang, L., Prabakaran, S., Wengenroth, M., Lockstone, H. E., Koethe, D., et al. (2008). Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. *Mol. Psychiatry.* 13, 1118–1128. doi: 10.1038/sj.mp.4002108
- Hye, A., Riddoch-Conteras, J., Baird, A. L., Ashton, N. J., Bazenet, C., Leung, R., et al. (2014). Plasma proteins predict conversion to dementia from prodromal disease. *Alzheimers Dement.* 10, 799–807.e2. doi: 10.1016/j.jalz.2014.05.1749
- Janaszewska, A., Klajnert-Maculewicz, B., Marcinkowska, M., Duchnowicz, P., Appelhans, D., Grasso, G., et al. (2017). Multivalent interacting glycodendrimer to prevent amyloid-peptide fibril formation induced by Cu(II): a multidisciplinary approach. *Nano Res.* 11, 1204–1226. doi: 10.1007/s12274-017-1734-9
- Jayaraman, S., Cavigliolo, G., and Gursky, O. (2012). Folded functional lipid-poor apolipoprotein A-I obtained by heating of high-density lipoproteins: relevance to high-density lipoprotein biogenesis. *Biochem. J.* 442, 703–712. doi: 10.1042/BJ20111831
- Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* 79, 926–935. doi: 10.1063/1.445869
- Kingwell, B. A., Chapman, M. J., Kontush, A., and Miller, N. E. (2014). HDL-targeted therapies: progress, failures and future. *Nat. Rev. Drug Discov.* 13, 445–464. doi: 10.1038/nrd4279
- Koch, S., Donarski, N., Goetze, K., Kreckel, M., Stuenkel, H. J., Buhmann, C., et al. (2001). Characterization of four lipoprotein classes in human cerebrospinal fluid. *J. Lipid Res.* 42, 1143–1151.
- Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., and Lazo, J. S. (2001). Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A β aggregation and toxicity. *Biochemistry* 40, 3553–3560. doi: 10.1021/bi002186k
- Lefterov, I., Fitz, N. F., Cronican, A. A., Fogg, A., Lefterov, P., Kodali, R., et al. (2010). Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. *J. Biol. Chem.* 285, 36945–36957. doi: 10.1074/jbc.M110.127738
- Lewis, T. L., Cao, D., Lu, H., Mans, R. A., Su, Y. R., Jungbauer, L., et al. (2010). Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. *J. Biol. Chem.* 285, 36958–36968. doi: 10.1074/jbc.M110.127829
- Lühns, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Döbeli, H., et al. (2005). 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. *Proc. Natl. Acad. Sci. U.S.A.* 102, 17342–17347.
- Mahley, R. W., Innerarity, T. L., Rall, S. C., and Weisgraber, K. H. (1984). Plasma lipoproteins: apolipoprotein structure and function. *J. Lipid Res.* 25, 1277–1294.
- Maisuradze, G. G., Liwo, A., and Scheraga, H. A. (2009). Principal component analysis for protein folding dynamics. *J. Mol. Biol.* 385, 312–329. doi: 10.1016/j.jmb.2008.10.018
- Mancini, S., Minniti, S., Gregori, M., Sancini, G., Cagnotto, A., Couraud, P. O., et al. (2016). The hunt for brain A β oligomers by peripherally circulating multifunctional nanoparticles: potential therapeutic approach for Alzheimer disease. *Nanomedicine* 12, 43–52. doi: 10.1016/j.nano.2015.09.003
- Mashiach, E., Schneidman-Duhovny, D., Andrusier, N., Nussinov, R., and Wolfson, H. J. (2008). FireDock: a web server for fast interaction refinement in molecular docking. *Nucleic Acids Res.* 36, W229–W232. doi: 10.1093/nar/gkn186
- McConnell, H. L., Kersch, C. N., Woltjer, R. L., and Neuwelt, E. A. (2017). The translational significance of the neurovascular unit. *J. Biol. Chem.* 292, 762–770. doi: 10.1074/jbc.r116.760215
- Merched, A., Xia, Y., Visvikis, S., Serot, J. M., and Siest, G. (2000). Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. *Neurobiol. Aging* 21, 27–30. doi: 10.1016/s0197-4580(99)00103-7
- Merino-Zamorano, C., Fernández-de Retana, S., Montañaola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., et al. (2016). Modulation of amyloid- β 1-40 transport by ApoA1 and ApoJ across an in vitro model of the blood-brain barrier. *J. Alzheimers Dis.* 53, 677–691. doi: 10.3233/JAD-150976

- Oram, J. F., and Heinecke, J. W. (2005). ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. *Physiol. Rev.* 85, 1343–1372. doi: 10.1152/physrev.00005.2005
- Paula-Lima, A. C., Triccerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., et al. (2009). Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. *Int. J. Biochem. Cell Biol.* 41, 1361–1370. doi: 10.1016/j.biocel.2008.12.003
- Phillips, M. C. (2013). New insights into the determination of HDL structure by apolipoproteins: thematic review series: high density lipoprotein structure, function, and metabolism. *J. Lipid Res.* 54, 2034–2048. doi: 10.1194/jlr.R034025
- Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., and Weisgraber, K. H. (1987). Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. *J. Biol. Chem.* 262, 14352–14360.
- Quan, L., Wu, J., Lane, L. A., Wang, J., Lu, Q., Gu, Z., et al. (2016). Enhanced detection specificity and sensitivity of Alzheimer's disease using Amyloid- β -Targeted quantum dots. *Bioconjug. Chem.* 27, 809–814. doi: 10.1021/acs.bioconchem.6b00019
- Robert, J., Button, E. B., Stukas, S., Boyce, G. K., Gibbs, E., Cowan, C. M., et al. (2017a). High-density lipoproteins suppress A β -induced PBMC adhesion to human endothelial cells in bioengineered vessels and in monoculture. *Mol. Neurodegener.* 12:60. doi: 10.1186/s13024-017-0201-0
- Robert, J., Button, E. B., Yuen, B., Gilmour, M., Kang, K., Bahrabadi, A., et al. (2017b). Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. *eLife* 6:e29595. doi: 10.7554/eLife.29595
- Robert, J., Stukas, S., Button, E., Cheng, W. H., Lee, M., Fan, J., et al. (2016). Reconstituted high-density lipoproteins acutely reduce soluble brain A β levels in symptomatic APP/PS1 mice. *Biochim. Biophys. Acta* 1862, 1027–1036. doi: 10.1016/j.bbdis.2015.10.005
- Roheim, P. S., Carey, M., Forte, T., and Vega, G. L. (1979). Apolipoproteins in human cerebrospinal fluid. *Proc. Natl. Acad. Sci. U.S.A.* 76, 4646–4649. doi: 10.1073/pnas.76.9.4646
- Sagare, A. P., Bell, R. D., and Zlokovic, B. V. (2012). Neurovascular dysfunction and faulty amyloid β -peptide clearance in Alzheimer disease. *Cold Spring Harb. Perspect. Med.* 2:a011452. doi: 10.1101/cshperspect.a011452
- Schägger, H., and von Jagow, G. (1987). Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. *Anal. Biochem.* 166, 368–379. doi: 10.1016/0003-2697(87)90587-2
- Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., and Wolfson, H. J. (2005). PatchDock and SymmDock: servers for rigid and symmetric docking. *Nucleic Acids Res.* 33, W363–W367.
- Selkoe, D. J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* 8, 595–608. doi: 10.15252/emmm.201606210
- Sevugan Chetty, P., Mayne, L., Kan, Z. Y., Lund-Katz, S., Englander, S. W., and Phillips, M. C. (2012). Apolipoprotein A-I helical structure and stability in discoidal high-density lipoprotein (HDL) particles by hydrogen exchange and mass spectrometry. *Proc. Natl. Acad. Sci. U.S.A.* 109, 11687–11692. doi: 10.1073/pnas.1209305109
- Shih, Y. H., Tsai, K. J., Lee, C. W., Shiesh, S. C., Chen, W. T., Pai, M. C., et al. (2014). Apolipoprotein C-III is an amyloid- β -binding protein and an early marker for Alzheimer's disease. *J. Alzheimers. Dis.* 41, 855–865. doi: 10.3233/JAD-140111
- Silva, R. A., Huang, R., Morris, J., Fang, J., Gracheva, E. O., Ren, G., et al. (2008). Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. *Proc. Natl. Acad. Sci. U.S.A.* 105, 12176–12181. doi: 10.1073/pnas.0803626105
- Slot, R. E., Van Harten, A. C., Kester, M. I., Jongbloed, W., Bouwman, F. H., Teunissen, C. E., et al. (2017). Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer's disease in non-demented elderly. *J. Alzheimers Dis.* 56, 687–697. doi: 10.3233/JAD-151068
- Stukas, S., Robert, J., Lee, M., Kulic, I., Carr, M., Tourigny, K., et al. (2014). Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. *J. Am. Heart Assoc.* 3:e001156. doi: 10.1161/JAHA.114.001156
- Vitali, C., Wellington, C. L., and Calabresi, L. (2014). HDL and cholesterol handling in the brain. *Cardiovasc. Res.* 103, 405–413. doi: 10.1093/cvr/cvu148
- Yu, X., and Zheng, J. (2012). Cholesterol promotes the interaction of Alzheimer β -amyloid monomer with lipid bilayer. *J. Mol. Biol.* 421, 561–571. doi: 10.1016/j.jmb.2011.11.006
- Zannis, V. I., Chroni, A., and Krieger, M. (2006). Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. *J. Mol. Med.* 84, 276–294. doi: 10.1007/s00109-005-0030-4

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Dal Magro, Simonelli, Cox, Formicola, Corti, Cassina, Nardo, Mantegazza, Salerno, Grasso, Deriu, Danani, Calabresi and Re. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.